<DOC>
	<DOCNO>NCT01681966</DOCNO>
	<brief_summary>LNP new extend release ( ER ) oily solution formulation ropivacaine intend local infiltration surgical wound . The purpose study determine ease usage administration LNP surgical setting , follow Pharmacokinetic ( PK ) profile LNP 72 hour evaluate duration analgesia witness surgical setting .</brief_summary>
	<brief_title>A Single-dose Open-Label Study Assess Safety Preliminary Efficacy PRF 110 Open Herniorrhaphy Surgery</brief_title>
	<detailed_description>LNP new extend release ( ER ) oily solution formulation ropivacaine intend local infiltration surgical wound . The formulation design slowly release ropivacaine 36-72 hour . By provide local analgesia long time span , need systemic analgesic expect reduced hospital stay may shorten . The purpose study determine ease usage administration LNP surgical setting , follow PK profile LNP 72 hour evaluate duration analgesia witness surgical setting .</detailed_description>
	<mesh_term>Pain , Postoperative</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Ropivacaine</mesh_term>
	<criteria>Male subject 1870 year age schedule undergo open one side herniorrhaphy surgery ; Subjects BMI le 30 kg/m2 ; Subjects good physical health ( need surgical procedure ) judge physical laboratory examination negative urine base screen drug abuse ; Subjects must agree refrain ingest analgesic medication least 2 day ( 5 halflives analgesic drug ) prior surgery ; refrain alcohol excessive caffeine intake day surgery 72 hour surgery ; Subject must capable reading , comprehend , sign informed consent form ; Subjects history melena significant hepatic , renal , endocrine , cardiac , neurological , psychiatric , gastrointestinal , pulmonary , hematologic , metabolic disorder ; Subjects history type cancer within 5 year surgery ; Subjects history alcohol substance abuse ; Subjects history uncontrolled hypertension ; Subjects know hypersensitivity local anesthetic drug ; Subjects hemoglobin concentration le 10.0 g/dL ; Subjects clinically significant abnormal lab result ( judge Principal Investigator ) ; Subjects atrial fibrillation/flutter , insert pacemaker , complete leave bundle branch block ( LBBB ) ECG ; myocardial infarction within 6 month prior surgery ; Subjects clinically significant abnormal ECG screening ; Subjects condition history judge Investigator place subject increase risk ; Subjects judge Investigator unable unwilling comply requirement protocol ; Subjects use investigational drug within 30 day prior enter study ; Subjects donate blood within 3 month prior start study ; Subjects member study site staff directly involve study relative Sponsor personnel involve study ;</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>